Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America
May 19, 2021 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Update on SADA Technology
May 13, 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments
May 06, 2021 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs to Announce First Quarter 2021 Financial and Operating Results on May 6, 2021
April 29, 2021 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the first quarter...
Y-mAbs Announces Data to be Presented at 2021 ASCO Annual Meeting
April 29, 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Submits Omburtamab Marketing Authorization Application to the European Medicines Agency
April 27, 2021 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Provides Regulatory Update on Omburtamab
April 20, 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces GPA33-SADA Data Presented at AACR
April 12, 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces 2020 Financial Results and Recent Corporate Developments
February 25, 2021 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a development-stage clinical biopharmaceutical company focused on the development and...
Y-mAbs Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
February 22, 2021 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...